Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Proteomics and Leishmaniasis: Potential Clinical Applications

Full text
Author(s):
Capelli-Peixoto, Janaina [1] ; Mule, Simon Ngao [2] ; Tano, Fabia Tomie [1] ; Palmisano, Giuseppe [2] ; Stolf, Beatriz Simonsen [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Leishmaniasis Lab, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, GlycoProte Lab, Dept Parasitol, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Review article
Source: PROTEOMICS CLINICAL APPLICATIONS; v. 13, n. 6 AUG 2019.
Web of Science Citations: 0
Abstract

Leishmaniases are diseases caused by protozoan parasites of the genus Leishmania. They are endemic in 98 countries, affect around 12 million people worldwide and may present several distinct clinical forms. Unfortunately, there are only a few drugs available for treatment of leishmaniasis, which are toxic and not always effective. Different parasite species and different clinical forms require optimization of the treatment or more specific therapies, which are not available. The emergence of resistance is also a matter of concern. Besides, diagnosis can sometimes be complicated due to atypical manifestations and associations with other pathologies. In this review, proteomic data are presented and discussed in terms of their application in important issues in leishmaniasis such as parasite resistance to chemotherapy, diagnosis of active disease in patients and dogs, markers for different clinical forms, identification of virulence factors, and their potential use in vaccination. It is shown that proteomics has contributed to the discovery of potential biomarkers for prognosis, diagnosis, therapeutics, monitoring of disease progression, treatment follow-up and identification of vaccine candidates for specific diseases. However, the authors believe its capabilities have not yet been fully explored for routine clinical analysis for several reasons, which will be presented in this review. (AU)

FAPESP's process: 17/26197-6 - Comparative proteomic analysis of promastigote membrane proteins from l. (l.) amazonensis PH8 and LV79 strains
Grantee:Fabia Tomie Tano
Support type: Scholarships in Brazil - Master
FAPESP's process: 17/04287-3 - Role of sCD100 in macrophage in vitro infection by Leishmania (Viannia) braziliensis and Leishmania (Leishmania) chagasi and in in vivo infection by Leishmania (Leishmania) amazonensis
Grantee:Janaína Capelli Peixoto
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 14/26777-4 - Role of cTXNPx and OPB in virulence and drug resistance in Leishmania L. amazonensis and search for new virulence factors by comparative proteomics
Grantee:Beatriz Simonsen Stolf
Support type: Regular Research Grants
FAPESP's process: 14/06863-3 - Post-translational modifications in cancer and parasite infection diagnosis: methodological approaches and biological implications
Grantee:Giuseppe Palmisano
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 18/18257-1 - Multi-user equipment approved in grant 14/06863-3: HPLC system configured for analysis of carbohydrates, amino acidis, peptides and glycoproteins
Grantee:Giuseppe Palmisano
Support type: Multi-user Equipment Program
FAPESP's process: 18/15549-1 - Post-translational modifications in Chagas Disease biological processes and diagnostics: novel methodological approaches and biological applications
Grantee:Giuseppe Palmisano
Support type: Research Grants - Young Investigators Grants - Phase 2
FAPESP's process: 17/04032-5 - Dissecting the pathogenesis of Chagas Disease by deep glycomics and glycoproteomics approaches
Grantee:Simon Ngao Mule
Support type: Scholarships in Brazil - Doctorate